Progyny, Inc. (NASDAQ:PGNY) Shares Purchased by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS lifted its position in Progyny, Inc. (NASDAQ:PGNYFree Report) by 29.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 686,064 shares of the company’s stock after purchasing an additional 156,910 shares during the period. Kornitzer Capital Management Inc. KS owned about 0.72% of Progyny worth $25,508,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in PGNY. RiverPark Advisors LLC lifted its stake in shares of Progyny by 54.0% in the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock valued at $40,000 after purchasing an additional 374 shares during the period. Rockefeller Capital Management L.P. increased its holdings in Progyny by 3,119.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,674 shares of the company’s stock worth $50,000 after acquiring an additional 1,622 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Progyny in the 3rd quarter worth $53,000. Lazard Asset Management LLC increased its holdings in Progyny by 45.2% in the 4th quarter. Lazard Asset Management LLC now owns 1,763 shares of the company’s stock worth $54,000 after acquiring an additional 549 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in Progyny in the 3rd quarter worth $58,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Progyny news, Chairman David J. Schlanger sold 20,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $38.50, for a total value of $770,000.00. Following the transaction, the chairman now owns 86,312 shares of the company’s stock, valued at $3,323,012. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Progyny news, Chairman David J. Schlanger sold 1,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $37.52, for a total value of $37,520.00. Following the transaction, the chairman now owns 83,631 shares of the company’s stock, valued at $3,137,835.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman David J. Schlanger sold 20,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $38.50, for a total transaction of $770,000.00. Following the completion of the transaction, the chairman now directly owns 86,312 shares in the company, valued at approximately $3,323,012. The disclosure for this sale can be found here. In the last quarter, insiders have sold 120,515 shares of company stock valued at $4,570,131. 14.30% of the stock is currently owned by insiders.

Progyny Trading Up 2.6 %

Shares of PGNY stock opened at $32.70 on Friday. The company’s 50-day moving average price is $36.68 and its 200-day moving average price is $35.67. The stock has a market cap of $3.14 billion, a price-to-earnings ratio of 52.74, a PEG ratio of 1.35 and a beta of 1.48. Progyny, Inc. has a twelve month low of $29.44 and a twelve month high of $44.95.

Progyny (NASDAQ:PGNYGet Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.04. The firm had revenue of $269.94 million for the quarter, compared to analysts’ expectations of $274.08 million. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The company’s revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS. As a group, equities research analysts predict that Progyny, Inc. will post 0.7 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on PGNY shares. Leerink Partnrs reissued an “outperform” rating on shares of Progyny in a report on Monday, February 26th. Truist Financial reissued a “buy” rating and issued a $46.00 price target on shares of Progyny in a report on Wednesday. KeyCorp cut their price target on shares of Progyny from $45.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, February 28th. SVB Leerink began coverage on shares of Progyny in a report on Monday, February 26th. They set an “outperform” rating and a $49.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $48.00 target price on shares of Progyny in a report on Wednesday, February 28th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $48.30.

Get Our Latest Report on PGNY

Progyny Company Profile

(Free Report)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Read More

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNYFree Report).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.